China's HBM Holdings H1 revenue rises on progress on mid-late clinical stage programs

HBM Holdings

27/08/2026 15:10

Overview
China biopharma firm's half-year revenue rose yr/yr to $122.5 mln
Net profit for the period declined compared to prior year
Basic and diluted EPS both fell to $0.08 from $0.09
Company highlighted progress on clinical pipeline and licensing deals

Outlook
Company did not provide specific financial guidance or outlook for the current or future periods

Result Drivers
CLINICAL PIPELINE ADVANCEMENT - Co attributed revenue growth to progress on key programs in mid-late clinical stage
LICENSING DEALS - Co highlighted new and expanded licensing agreements as contributing to results
STRATEGIC COLLABORATION - Co entered multi-year global collaboration with Bristol Myers Squibb for antibody development

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
H1 Revenue
 
$122.5 mln
 

Analyst Coverage
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy."
Wall Street's median 12-month price target for Hbm Holdings Ltd is HK$20.00, about 22.7% above its August 27 closing price of HK$16.30
The stock recently traded at 20 times the next 12-month earnings vs. a P/E of 19 three months ago

Reuters Recommended Reads
Aug 27 - China's CStone Pharmaceuticals H1 revenue soars on drug sales
Aug 24 - China's RemeGen H1 revenue soars on drug sales, AbbVie deal
Aug 26 - China's Jiangsu says it will support pharmaceutical firms' global M&A, licensing

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)